Multivariable analysis of factors affecting NRM, cumulative incidence of relapse and LFS
| Variable . | Risk ratio . | 95% CI . | P . |
|---|---|---|---|
| Nonrelapse mortality | |||
| Age at HSCT | |||
| ≥13 y vs <13 y | 1.88 | 1.05-3.35 | .033 |
| Donor | |||
| MMUD vs MUD | 4.35 | 1.97-9.60 | <.001 |
| Haploidentical vs MUD | 1.37 | 0.52-3.56 | .523 |
| Relapse | |||
| Diagnosis | |||
| AML vs ALL | 1.20 | 0.52-3.46 | .737 |
| Prognosis | |||
| Poor vs good | 3.43 | 1.69-6.94 | .001 |
| MRD | |||
| ≥1 × 10−3 vs <1 × 10−3 | 2.97 | 1.32-6.67 | .008 |
| Conditioning regimen | |||
| Busulfan vs TBI | 1.51 | 0.51-4.45 | .452 |
| Treosulfan vs TBI | 1.46 | 0.64-3.56 | .370 |
| Donor | |||
| MMUD vs MUD | 0.52 | 0.25-1.10 | .088 |
| Haploidentical vs MUD | 0.71 | 0.33-1.54 | .383 |
| Leukemia-free-survival | |||
| Sex | |||
| Female vs male | 1.63 | 0.97-2.75 | .065 |
| Age at HSCT | |||
| ≥13 y vs <13 y | 0.94 | 0.52-1.72 | .842 |
| Diagnosis | |||
| AML vs ALL | 0.81 | 0.33-1.98 | .641 |
| Prognosis | |||
| Poor vs good | 3.00 | 169-5.31 | <.001 |
| MRD level | |||
| ≥1 × 10−3 vs <1 × 10−3 | 2.90 | 1.47-5.71 | .002 |
| Conditioning regimen | |||
| Busulfan vs TBI | 1.22 | 0.52-2.86 | .648 |
| Treosulfan vs TBI | 1.45 | 0.64-3.27 | .372 |
| Donor | |||
| MMUD vs MUD | 0.93 | 0.51-1.69 | .800 |
| Haploidentical vs MUD | 0.69 | 0.36-1.32 | .258 |
| Variable . | Risk ratio . | 95% CI . | P . |
|---|---|---|---|
| Nonrelapse mortality | |||
| Age at HSCT | |||
| ≥13 y vs <13 y | 1.88 | 1.05-3.35 | .033 |
| Donor | |||
| MMUD vs MUD | 4.35 | 1.97-9.60 | <.001 |
| Haploidentical vs MUD | 1.37 | 0.52-3.56 | .523 |
| Relapse | |||
| Diagnosis | |||
| AML vs ALL | 1.20 | 0.52-3.46 | .737 |
| Prognosis | |||
| Poor vs good | 3.43 | 1.69-6.94 | .001 |
| MRD | |||
| ≥1 × 10−3 vs <1 × 10−3 | 2.97 | 1.32-6.67 | .008 |
| Conditioning regimen | |||
| Busulfan vs TBI | 1.51 | 0.51-4.45 | .452 |
| Treosulfan vs TBI | 1.46 | 0.64-3.56 | .370 |
| Donor | |||
| MMUD vs MUD | 0.52 | 0.25-1.10 | .088 |
| Haploidentical vs MUD | 0.71 | 0.33-1.54 | .383 |
| Leukemia-free-survival | |||
| Sex | |||
| Female vs male | 1.63 | 0.97-2.75 | .065 |
| Age at HSCT | |||
| ≥13 y vs <13 y | 0.94 | 0.52-1.72 | .842 |
| Diagnosis | |||
| AML vs ALL | 0.81 | 0.33-1.98 | .641 |
| Prognosis | |||
| Poor vs good | 3.00 | 169-5.31 | <.001 |
| MRD level | |||
| ≥1 × 10−3 vs <1 × 10−3 | 2.90 | 1.47-5.71 | .002 |
| Conditioning regimen | |||
| Busulfan vs TBI | 1.22 | 0.52-2.86 | .648 |
| Treosulfan vs TBI | 1.45 | 0.64-3.27 | .372 |
| Donor | |||
| MMUD vs MUD | 0.93 | 0.51-1.69 | .800 |
| Haploidentical vs MUD | 0.69 | 0.36-1.32 | .258 |
Subgroups including fewer than 5 patients were not shown in the table.